
Insecticides India Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company expects a decent double-digit growth every year in sales and revenues.
- Around half a dozen new product launches, including new technicals and biologicals, are planned annually to drive growth.
- Biological segment growth is expected to be gradual, targeting INR10-15 crores incremental revenue in early years.
- Focus on launching IP-protected, new generation solutions with less competition to create strong brands.
- Volume growth is anticipated alongside price pressures, with double-digit volume growth seen in the current year continuing.
- The Maharatna and Focused Maharatna product categories are key growth drivers, with focus to increase their contribution to 65-70% of sales in 2-3 years.
- Export and B2B segments are also expected to grow, supported by new registrations and product introductions.
- Overall, the company is confident of growing better than the industry with improved top line and bottom line performance in coming years.
See what Insecticides India management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The management did not explicitly mention any current or future plans for fundraising through debt or equity in the discussed sections.
- Rajesh Aggarwal highlighted that the company is currently debt-free and has sufficient funds to support growth and investments.
- Focus is on internal growth, new product launches, backward integration, and R&D to improve margins and scale.
- There was no indication of plans to raise additional capital externally; instead, growth and expansion are being funded through existing resources and operational cash flows.
See what Insecticides India management said on order book — free account, 30 seconds.
Capex plans
Yes- The company is focusing on expanding its manufacturing capabilities, including increasing the number of reactors from around 150 to roughly 300 for manufacturing technicals and backward integration.
- New technicals are being introduced; eight technicals are being stopped while six new technicals are planned for the domestic market within 3-4 months.
- Investment is made in strengthening teams across marketing, strategy, manufacturing, R&D, and the Board by adding senior professionals.
- Major insecticides manufacturing will move to the Chopanki plant to improve returns.
- The company is investing in digitization through a program named IL360 to improve last-mile connectivity with retailers and farmers for better market reach.
- R&D spend is expected around INR12 to 15 crores next year, with major investment coming from the Japanese partner.
- Plans to launch new patented products and import more from Japan (Nissan partnership), targeting INR500+ crores in sales from Japanese products next year.
Track Insecticides India — get its next earnings analysis in your feed
How does Insecticides India rank vs peers in Fertilizers & Agrochemicals?
Pro featureHow does Insecticides India rank in Fertilizers & Agrochemicals?
Compare Insecticides India against every Fertilizers & Agrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Insecticides India's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Madhya Bharat Agro Products (Q2 FY27)
Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo
- Dhansa Labs (Q2 FY27)
1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Aristo Bio-Tech (Q2 FY27)
1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu
- Krishana Phoschem (Q2 FY27)
Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres